Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03866382
Title	Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	National Cancer Institute (NCI)
Indications	papillary renal cell carcinoma collecting duct carcinoma sarcomatoid transitional cell carcinoma Leydig cell tumor prostate small cell carcinoma bladder urothelial carcinoma urinary bladder small cell neuroendocrine carcinoma bladder adenocarcinoma penile cancer bladder squamous cell carcinoma Sertoli cell tumor sarcomatoid renal cell carcinoma chromophobe renal cell carcinoma
Therapies	Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab
Age Groups:	senior \| adult
Covered Countries	USA